Nascent Biotech Inc (OTCMKTS:NBIO) shares were up 12.4% on Friday . The stock traded as high as $0.16 and last traded at $0.16, approximately 1,000 shares were traded during trading. A decline of 91% from the average daily volume of 11,693 shares. The stock had previously closed at $0.14.
The company’s 50 day moving average is $0.18 and its two-hundred day moving average is $0.18.
Nascent Biotech Company Profile (OTCMKTS:NBIO)
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer.
Featured Article: Operating Income
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.